Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Umberto Vitolo

Showing results (131-140 of 212) with videos related to

Pageof 22
Sort By:
British Journal of Haematology|December 24, 2021
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trialAnnalisa Chiappella, Fary Diop, Claudio Agostinelli, et al.
Blood Advances|March 2, 2021
End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYALale Kostakoglu, Maurizio Martelli, Laurie H Sehn, et al.
Annals of Hematology|December 25, 2019
The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatmentsAlessia Bari, Raffaella Marcheselli, Stefano Sacchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized StudyEmanuele Zucca, Annarita Conconi, Daniele Laszlo, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 30, 2015
Role of Chemotherapy and Allografting in the Treatment of Acute Lymphoblastic LeukemiaLuisa Giaccone, Ernesta Audisio, Benedetto Bruno, et al.
Annals of Hematology|November 21, 2020
Correction to: The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of pet-guided treatmentsAlessia Bari, Raffaella Marcheselli, Stefano Sacchi, et al.
British Journal of Haematology|January 21, 2021
A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL)Carola Boccomini, Marco Ladetto, Luigi Rigacci, et al.
The New England Journal of Medicine|July 22, 2011
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is plannedSimonetta Viviani, Pier Luigi Zinzani, Alessandro Rambaldi, et al.
The Lancet. Haematology|August 8, 2020
Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 studyJean-Marie Michot, Reda Bouabdallah, Umberto Vitolo, et al.
Leukemia|July 25, 2021
Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphomaAlessandra Rossi, Stefania Orecchioni, Paolo Falvo, et al.
Pageof 22

Showing results (131-140 of 212) with videos related to

Sort By:
Pageof 22
British Journal of Haematology|December 24, 2021
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trialAnnalisa Chiappella, Fary Diop, Claudio Agostinelli, et al.
Blood Advances|March 2, 2021
End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYALale Kostakoglu, Maurizio Martelli, Laurie H Sehn, et al.
Annals of Hematology|December 25, 2019
The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatmentsAlessia Bari, Raffaella Marcheselli, Stefano Sacchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized StudyEmanuele Zucca, Annarita Conconi, Daniele Laszlo, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 30, 2015
Role of Chemotherapy and Allografting in the Treatment of Acute Lymphoblastic LeukemiaLuisa Giaccone, Ernesta Audisio, Benedetto Bruno, et al.
Annals of Hematology|November 21, 2020
Correction to: The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of pet-guided treatmentsAlessia Bari, Raffaella Marcheselli, Stefano Sacchi, et al.
British Journal of Haematology|January 21, 2021
A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL)Carola Boccomini, Marco Ladetto, Luigi Rigacci, et al.
The New England Journal of Medicine|July 22, 2011
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is plannedSimonetta Viviani, Pier Luigi Zinzani, Alessandro Rambaldi, et al.
The Lancet. Haematology|August 8, 2020
Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 studyJean-Marie Michot, Reda Bouabdallah, Umberto Vitolo, et al.
Leukemia|July 25, 2021
Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphomaAlessandra Rossi, Stefania Orecchioni, Paolo Falvo, et al.
Pageof 22